Table 2 Baseline characteristics
From: An historical and contemporary review of endovascular therapy for acute ischemic stroke
Age (median) | Male (%) | NIHSS (median) | Vessel occlusion | Tandem lesion (extrancranial ICA occlusion) | ASPECTS (median) | IVT (%) | Retrievable stent (%) | |
|---|---|---|---|---|---|---|---|---|
MR RESCUE | 66 | 50 | 16 | 71% ICA or M1* | nr | predicted core 36 ml* | 47* | 0 |
IMS III | 69 | 50 | 17 | 18% of EVT group had no occlusion | nr | nr | 100 | 4 |
SYNTHESIS | 66 | 59 | 13 | 2% no occlusion | nr | nr | 0 | 41 |
PISTE | 67 | 39 | 18 | 90% carotid T/L or M1 | 3% | 9 | 100 | 68 |
THERAPY | 67 | 62 | 17 | 89% I-ICA or M1 | excluded | 7.5 | 100 | 13% (majority used aspiration thrombectomy) |
MR CLEAN | 66 | 58 | 17 | 92% I-ICA, carotid T or M1 | 32% | 9 | 87 (44% drip & ship) | 82 |
ESCAPE | 71 | 48 (87% white) | 16 | 96% carotid T/L or M1 | 13% | 9 | 73 | 73 |
EXTEND_IA | 69 | 49 | 17 | 88% I-ICA or M1 | n/r | n/r (median core 12 ml) | 100 | 100 |
SWIFT PRIME | 65 | 55 (89% white) | 17 | 86% carotid T/L or M1 | excluded | 9 | 100 (44% drip & ship) | 100 |
REVASCAT | 65 | 55 | 17 | 90% carotid T/L or M1 | 19 | 7 | 70 | 70 |
THRACE | 66 | 57 | 18 | 98% ICA or M1 | excldued | nr | 100 (100% mothership) | 77 |